Core Viewpoint - Elis has disclosed the purchase of its own shares from July 14 to July 18, 2025, as part of its share buyback program authorized by the General Shareholders' Meeting on May 22, 2025 [2]. Summary by Relevant Sections Share Buyback Details - The total number of shares acquired during the buyback period is 111,716 shares, with an average purchase price of €24.4057 [2]. - The transactions were conducted on two platforms: XPAR and DXE, with the highest daily volume recorded on July 16, 2025, at 28,813 shares [2]. Purpose of Share Buybacks - The share buyback operations aim to cover maturing performance share plans and allocate free shares to employees as part of the "Elis for All 2025" international employee shareholding plan [2]. - Additionally, the shares are intended to be canceled in accordance with the resolution passed during the Combined General Meeting on May 22, 2025 [2].

Core Viewpoint - Wolters Kluwer has repurchased 196,897 ordinary shares for €27.4 million, part of a larger share buyback program aimed at repurchasing up to €1 billion in 2025 [2][3]. Share Buyback Program - The share buyback program was announced on February 26, 2025, with a total intended repurchase of €1 billion during the year [3]. - Cumulative shares repurchased to date in 2025 amount to 3,885,856, with a total consideration of €590.6 million and an average share price of €151.99 [3]. - For the period from May 8, 2025, to July 28, 2025, the company has engaged third parties to execute €350 million of buybacks [3]. Treasury Shares and Capital Reduction - Shares repurchased are held as treasury shares and will be used for capital reduction through share cancellation [4]. Company Overview - Wolters Kluwer reported annual revenues of €5.9 billion for 2024 and serves customers in over 180 countries, employing approximately 21,900 people [5]. - The company is headquartered in Alphen aan den Rijn, the Netherlands, and is listed on Euronext Amsterdam [6].

Core Viewpoint - Wolters Kluwer has repurchased 196,897 shares for €27.4 million, part of a larger share buyback program aimed at repurchasing up to €1 billion in 2025 [2][3]. Share Buyback Program - The share buyback program was announced on February 26, 2025, with a total planned repurchase of up to €1 billion during the year [3]. - As of the report date, a cumulative total of 3,885,856 shares have been repurchased, amounting to €590.6 million, with an average share price of €151.99 [3]. - For the period from May 8, 2025, to July 28, 2025, the company has engaged third parties to execute €350 million of buybacks [3]. Financial Overview - Wolters Kluwer reported annual revenues of €5.9 billion for 2024 and operates in over 180 countries with approximately 21,900 employees [6]. - The company is headquartered in Alphen aan den Rijn, Netherlands, and is listed on Euronext Amsterdam [6][7]. Shareholder Impact - Shares repurchased are held as treasury shares and will be used for capital reduction through share cancellation [4].

Core Viewpoint - Novartis reported strong Q2 2025 results with double-digit growth in net sales and core operating income, driven by successful product launches and pipeline advancements, alongside a commitment to a significant share buyback program [3][4][5]. Financial Performance - Q2 2025 net sales reached USD 14.1 billion, a 12% increase year-over-year, with constant currency growth of 11% [4][30]. - Operating income for Q2 2025 was USD 4.9 billion, reflecting a 21% increase, while net income rose to USD 4.0 billion, up 24% [4][9]. - Core operating income was USD 5.9 billion, a 20% increase, with a core operating income margin of 42.2% [10][30]. - Free cash flow for Q2 2025 was USD 6.3 billion, a 37% increase compared to the previous year [10][30]. - For H1 2025, net sales totaled USD 27.3 billion, up 12%, and core operating income increased by 21% to USD 11.5 billion [11][13]. Product Performance - Key growth drivers included Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc), and Pluvicto (+30% cc) [5][16]. - The top 20 brands generated USD 11.6 billion in Q2 2025, with a 16% increase year-over-year [17][18]. Strategic Initiatives - Novartis announced an up-to USD 10 billion share buyback program to enhance shareholder returns [3][5]. - The company raised its full-year 2025 guidance for core operating income growth to low teens, while maintaining high single-digit sales growth expectations [5][28]. Research and Development - Significant pipeline milestones included positive Phase III results for Pluvicto in hormone-sensitive prostate cancer and FDA approval for Vanrafia for IgAN [5][19][21]. - Ongoing trials and studies showed promising results for various therapies, including Kisqali and Scemblix, with plans for further regulatory submissions [22][23]. Capital Structure - As of June 30, 2025, net debt increased to USD 23.8 billion, primarily due to cash outflows for dividends and share repurchases [26]. - The company maintains a strong capital structure with a focus on balanced capital allocation [24][25].

Core Insights - CF Industries Holdings, Inc. (CF) shares have increased by 28% over the past three months, outperforming the industry's 18.9% rise and the S&P 500's approximately 15.7% increase during the same period [1][9]. Group 1: Market Dynamics - CF Industries is benefiting from strong global demand for nitrogen fertilizers, driven by robust agricultural activity and recovery in industrial demand post-pandemic [3][4]. - The company projects favorable global supply-demand dynamics for nitrogen in the near term, supported by a low global corn stocks-to-use ratio and weak production economics in Europe [4][5]. - In North America, strong nitrogen demand is anticipated during the spring planting season, with an expected increase in corn acreage by 2025 due to higher returns compared to soybeans [5]. Group 2: Financial Performance - CF Industries generated $586 million in net cash from operating activities in the first quarter, marking a 32% increase year-over-year [6]. - The company repurchased 5.4 million shares for $434 million in the first quarter, with approximately $630 million remaining under the existing $3 billion share buyback program [6]. - A new $2 billion share repurchase program has been approved by the board, set to run through 2029 [6]. Group 3: Revenue Growth - Rising nitrogen prices have led to a nearly 13% year-over-year increase in net sales, reaching $1,663 million in the first quarter [7][10]. - The average selling prices for most core products increased due to higher global energy costs, which raised market-clearing prices to meet global demand [10].

Disclosure of trading in own shares occurred from July 7 to July 11, 2025 Saint-Cloud, July 15, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from July 7 to July 11, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily ...

Group 1 - Aalberts has repurchased 2,500 shares from July 7 to July 11, 2025, for a total of EUR 78,823.16, averaging EUR 31.53 per share [1] - A cumulative total of 2,002,324 shares has been repurchased under the buyback program, amounting to EUR 59,718,534 [2] - The share buyback program is authorized by the AGM held on May 23, 2024, and complies with Market Abuse Regulation 596/2014 and Commission Delegated Regulation 2016/1052 [3]

Group 1 - ASM International N.V. has conducted share repurchases totaling 1,272 shares at an average price of €508.50, amounting to a total repurchased value of €646,807 [1] - The share buyback program, initiated on April 30, 2025, has a total budget of €150 million, with 40.4% of the program completed to date [2] - ASM International specializes in designing and manufacturing equipment and process solutions for semiconductor device production, with operations in the United States, Europe, and Asia [2]

Core Viewpoint - Siili Solutions Plc has conducted a share repurchase, acquiring a total of 900 shares at an average price of 6.60 EUR per share, amounting to a total cost of 5,940 EUR, which increases its total holdings to 29,128 shares [1]. Group 1 - The share repurchase took place on July 14, 2025, on the Helsinki Stock Exchange [1]. - The repurchase is in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052 [1].

The total number of shares repurchased under this programme to date is 4,282,329 ordinary shares for a total consideration of EUR 83.4 million. More details on the progress of the buyback programme are available here. This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(3) of the EU Regulation 2016/1052 that contains technical standards for buyback programmes. # # # PRESS RELEASE Amsterdam, July 14, 2025 JDE Peet's (EURONEXT: JDEP), the world's leading ...